Antitumor activity of benzaldehyde

Area of Science:

• Oncology
• Pharmacology

Background:

• Advanced and inoperable carcinomas present significant treatment challenges.
• Novel therapeutic agents are needed to improve outcomes for terminal cancer patients.

Purpose of the Study:

• To evaluate the efficacy and safety of beta-cyclodextrin benzaldehyde inclusion compound (CDBA) in patients with advanced cancers.
• To investigate the potential of CDBA to induce differentiation in cancer cells.

Main Methods:

• A total of 102 patients with advanced or serious tumor conditions received CDBA orally or rectally at 10 mg/kg/day.
• Treatment involved daily doses divided into four administrations.
• Patient responses and toxic effects were monitored during long-term administration.

Main Results:

• No significant toxic effects, including hematologic or biochemical disturbances, were observed with long-term CDBA administration.
• Among 57 evaluable patients, 19 achieved complete response and 10 had partial response (≥50% regression).
• Treatment of squamous cell carcinoma led to cancer cell differentiation into keratinized cells, resembling pearls.

Conclusions:

• CDBA demonstrates a favorable safety profile and potential anti-cancer activity in advanced malignancies.
• The observed differentiation effect in squamous cell carcinoma suggests a novel mechanism of action for CDBA.
• Further research into CDBA as a therapeutic agent for cancer is warranted.